Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease
Petr Novák, Reinhold Schmidt, Eva Kontseková, et al.
Alzheimer s Research & Therapy (2018) Vol. 10, Iss. 1
Open Access | Times Cited: 119

Showing 1-25 of 119 citing articles:

History and progress of hypotheses and clinical trials for Alzheimer’s disease
Peipei Liu, Yi Xie, Xiao‐Yan Meng, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 571
Peptide-Based Vaccines: Current Progress and Future Challenges
Ryan J. Malonis, Jonathan R. Lai, Olivia Vergnolle
Chemical Reviews (2019) Vol. 120, Iss. 6, pp. 3210-3229
Open Access | Times Cited: 495
Alzheimer's disease: Recent treatment strategies
Miguel Vaz, Samuel Silvestre
European Journal of Pharmacology (2020) Vol. 887, pp. 173554-173554
Closed Access | Times Cited: 438
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Chenghuan Song, Jiyun Shi, Pingao Zhang, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 163
It’s all about tau
Cheril Tapia‐Rojas, Fabian Cabezas-Opazo, Carol A. Deaton, et al.
Progress in Neurobiology (2018) Vol. 175, pp. 54-76
Open Access | Times Cited: 162
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations
Bradley F. Boeve, Adam L. Boxer, Fiona Kumfor, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 3, pp. 258-272
Open Access | Times Cited: 135
Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review
Tien-Wei Yu, Hsien‐Yuan Lane, Chieh‐Hsin Lin
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8208-8208
Open Access | Times Cited: 128
ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease
Petr Novák, Branislav Kováčech, Stanislav Katina, et al.
Nature Aging (2021) Vol. 1, Iss. 6, pp. 521-534
Closed Access | Times Cited: 123
Tau-targeting therapies for Alzheimer disease: current status and future directions
Erin E. Congdon, Changyi Ji, Amber M. Tetlow, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 12, pp. 715-736
Closed Access | Times Cited: 121
Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks
Yong Peng, Hong Jin, Ya-hui Xue, et al.
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 67
Targeting aging and age-related diseases with vaccines
R. H. Wu, Fei Sun, Weiqi Zhang, et al.
Nature Aging (2024) Vol. 4, Iss. 4, pp. 464-482
Closed Access | Times Cited: 25
Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective
Paul J. Derry, Muralidhar L. Hegde, George R. Jackson, et al.
Progress in Neurobiology (2019) Vol. 184, pp. 101716-101716
Open Access | Times Cited: 121
Current and emerging avenues for Alzheimer's disease drug targets
Raúl Loera‐Valencia, Ángel Cedazo‐Mínguez, Paul-Ariel Kenigsberg, et al.
Journal of Internal Medicine (2019) Vol. 286, Iss. 4, pp. 398-437
Open Access | Times Cited: 119
Drug Development for Alzheimer’s Disease: Microglia Induced Neuroinflammation as a Target?
Yuan Dong, Xiaoheng Li, Jinbo Cheng, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 3, pp. 558-558
Open Access | Times Cited: 118
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
Steven S. Plotkin, Neil R. Cashman
Neurobiology of Disease (2020) Vol. 144, pp. 105010-105010
Open Access | Times Cited: 109
New Insights Into Drug Discovery Targeting Tau Protein
Yoshiyuki Soeda, Akihiko Takashima
Frontiers in Molecular Neuroscience (2020) Vol. 13
Open Access | Times Cited: 105
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
Francesco Panza, Madia Lozupone, Davide Seripa, et al.
Nature Reviews Neurology (2020) Vol. 16, Iss. 4, pp. 213-228
Closed Access | Times Cited: 96
RETRACTED ARTICLE: Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer’s disease
Chunhong Gao, Xiaoyang Chu, Wei Gong, et al.
Journal of Nanobiotechnology (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 88
Curcumin and Its Derivatives as Theranostic Agents in Alzheimer’s Disease: The Implication of Nanotechnology
Umair Shabbir, Momna Rubab, Akanksha Tyagi, et al.
International Journal of Molecular Sciences (2020) Vol. 22, Iss. 1, pp. 196-196
Open Access | Times Cited: 87
Advances and considerations in AD tau-targeted immunotherapy
Alice Bittar, Nemil Bhatt, Rakez Kayed
Neurobiology of Disease (2019) Vol. 134, pp. 104707-104707
Open Access | Times Cited: 84
Targeting tau: Clinical trials and novel therapeutic approaches
Lawren VandeVrede, Adam L. Boxer, Manuela Polydoro
Neuroscience Letters (2020) Vol. 731, pp. 134919-134919
Open Access | Times Cited: 80
Immunotherapies for Neurodegenerative Diseases
Ibrahim Mortada, Raymond Farah, Sanaa Nabha, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 78
The role of the immune system in Alzheimer’s disease
Kaimin Wu, Ya-Ru Zhang, Yu‐Yuan Huang, et al.
Ageing Research Reviews (2021) Vol. 70, pp. 101409-101409
Closed Access | Times Cited: 78
Current Status of Clinical Trials on Tau Immunotherapies
Changyi Ji, Einar M. Sigurdsson
Drugs (2021) Vol. 81, Iss. 10, pp. 1135-1152
Open Access | Times Cited: 75
New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease
Feng Zhang, Rujia Zhong, Cheng Cheng, et al.
Acta Pharmacologica Sinica (2020) Vol. 42, Iss. 9, pp. 1382-1389
Open Access | Times Cited: 73
Page 1 - Next Page

Scroll to top